| |
Before PEPa
|
Observation period
|
|---|
|
Day 1
|
Day 2
|
Day 3
|
Day 4
|
Day 5
|
Day 6
|
Day 7
|
|---|
|
Informed consent
|
X
| | | | | | | |
|
Clinical assessmentb
|
X
| | | | | | | |
|
Laboratory testc
|
X
| | | | | | | |
|
PEPa
| |
X
|
X
|
X
| | | | |
|
Fever
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
|
Respiratory symptomsd
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
|
Immunochromatographic testinge
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
|
Adverse events
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
- aPost-exposure prophylaxis
- bClinical assessment: history including age, sex, body weight, influenza vaccination, past infection with influenza, underlying disease and medical history
- cLaboratory test: hemoglobin, white blood count, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine
- dRespiratory symptoms: cough or sneezing
- eIf the close contacts with index patients with influenza have fever or respiratory symptoms within 7 days after PEP, immunochromatographic testing of influenza will be carried out
